Revenue is increasing over prior year period but expenses in the last quarter were up mainly due to the costs of getting the FDA trial up and running .
Sales in upcoming quarters should be growing as their product becomes available in more parts of the world and recell sales appear to be gaining traction.
I believe they are still getting $1.5m in military grant money and with the existing cash and fortrend capital money they should have more than enough to get FDA approval and become cashflow positive.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.70 |
Change
0.020(1.19%) |
Mkt cap ! $121.1M | |||
| Open | High | Low | Value | Volume |
| $1.71 | $1.74 | $1.70 | $515.3K | 300.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 5952 | $1.70 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.71 | 1820 | 5 |
View Market Depth
| Last trade - 15.00pm 18/07/2025 (20 minute delay) ? |
| AVH (ASX) Chart |